Grant: Collaborative Health Research Projects
University of Toronto
$309,956.00
A combined nanotechnology and surgical strategy to treating liver cancer
FY 2017-18
Summary
Liver cancer is currently difficult to treat and the required amount of chemotherapeutics to successfully treat this cancer ishigh. In this project, we plan to remove the liver from the host and infuse the liver with a nanoparticle that contains thecancer-fighting drug 5-fluorouracil and that can target macrophage tumor infiltrating cells. These cells support the survival ofthe tumor system. This nanocontainer infused liver will be re-implanted into the animal. The nanoparticle breaks apart after2-3 weeks to release the drug and kill the macrophage tumor infiltrating cells and therefore, destroying the tumor. Thisshould lead to an increase in the survival of the animal. Our commercial partner specializes in developing drugs and proteinsthat can target liver cancer cells. Combining the expertise of the Therapure Biopharma with the unique expertise ofresearchers in nanotechnology, liver, surgery, and physics from the academic side will lead to new strategies to treat livercancer.
Program
Collaborative Health Research Projects
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
493619-2016
Name nom
Chan, Warren
Department département
Biomaterials and Biomedical Engineering, Inst. of (IBBME)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2016
Award amount
309956
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2 & 3
Nb partie
3
Application title
A combined nanotechnology and surgical strategy to treating liver cancer
Keyword
NSERC
Application summary
Liver cancer is currently difficult to treat and the required amount of chemotherapeutics to successfully treat this cancer ishigh. In this project, we plan to remove the liver from the host and infuse the liver with a nanoparticle that contains thecancer-fighting drug 5-fluorouracil and that can target macrophage tumor infiltrating cells. These cells support the survival ofthe tumor system. This nanocontainer infused liver will be re-implanted into the animal. The nanoparticle breaks apart after2-3 weeks to release the drug and kill the macrophage tumor infiltrating cells and therefore, destroying the tumor. Thisshould lead to an increase in the survival of the animal. Our commercial partner specializes in developing drugs and proteinsthat can target liver cancer cells. Combining the expertise of the Therapure Biopharma with the unique expertise ofresearchers in nanotechnology, liver, surgery, and physics from the academic side will lead to new strategies to treat livercancer.
